Real World Treatment Patterns for Castration-Sensitive Prostate Cancer Between 2012 and 2024: A Systematic Review
Author(s)
Bougchiche Meïssa, BSc, MSc1, Félix Morin, BSc,MSc1, Ivan Yanev, BSc, MSc2, Alice Dragomir, PhD1;
1University of Montreal, Faculty of pharmacy, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada
1University of Montreal, Faculty of pharmacy, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada
Presentation Documents
OBJECTIVES: The management of prostate cancer has evolved significantly with the introduction of androgen deprivation therapy (ADT) combined with docetaxel in 2015 and novel hormonal therapies (NHTs) in 2016. However, the adoption and utilization patterns of these therapies in real-world settings remain poorly characterized for castration-sensitive prostate cancer (CSPC). This systematic review aims to describe treatment patterns and utilization trends for CSPC between 2012 and 2024 in real-world contexts and their alignment with the clinical guidelines.
METHODS: A systematic review was conducted across EMBASE, MEDLINE, WOS, CINAHL, and gray literature for studies published in English or French from 2012 to 2024. Eligible studies included observational real-world studies, such as retrospective or prospective cohorts, case-control, cross-sectional studies, and systematic reviews. Randomized clinical trials (RCTs), case reports, and conference abstracts were excluded. The review focused on ADT usage, including combinations with docetaxel and/or NHTs (abiraterone, apalutamide, enzalutamide, and darolutamide) or with other treatments. Two reviewers independently performed study selection and data extraction. Data synthesis involves qualitative and quantitative analyses of treatment patterns across years and countries.
RESULTS: Twenty studies were included, covering data from 14 countries: Canada, USA, EU5, Norway, the Netherlands, Australia, Singapore, Japan, China, and Belgium. ADT alone remains the most used therapy across all years, with utilization rates between 35% and 79%. ADT+docetaxel was more common prior to 2017, ranging from 25% to 31%, but usage dropped below 10% by 2019. ADT+NHTs started below 5% in 2016 but surpassed ADT+docetaxel usage by 2017, reaching 10% to 17% in North America and Europe. Adoption in Asian countries was slower. By 2018 and 2019, ADT+NHTs utilization peaked at 10% to 30%.
CONCLUSIONS: This review offers healthcare providers valuable insights into CSPC treatment trends. The findings aim to refine clinical guidelines, inform policymaking, improve resource allocation, and enhance market understanding globally.
METHODS: A systematic review was conducted across EMBASE, MEDLINE, WOS, CINAHL, and gray literature for studies published in English or French from 2012 to 2024. Eligible studies included observational real-world studies, such as retrospective or prospective cohorts, case-control, cross-sectional studies, and systematic reviews. Randomized clinical trials (RCTs), case reports, and conference abstracts were excluded. The review focused on ADT usage, including combinations with docetaxel and/or NHTs (abiraterone, apalutamide, enzalutamide, and darolutamide) or with other treatments. Two reviewers independently performed study selection and data extraction. Data synthesis involves qualitative and quantitative analyses of treatment patterns across years and countries.
RESULTS: Twenty studies were included, covering data from 14 countries: Canada, USA, EU5, Norway, the Netherlands, Australia, Singapore, Japan, China, and Belgium. ADT alone remains the most used therapy across all years, with utilization rates between 35% and 79%. ADT+docetaxel was more common prior to 2017, ranging from 25% to 31%, but usage dropped below 10% by 2019. ADT+NHTs started below 5% in 2016 but surpassed ADT+docetaxel usage by 2017, reaching 10% to 17% in North America and Europe. Adoption in Asian countries was slower. By 2018 and 2019, ADT+NHTs utilization peaked at 10% to 30%.
CONCLUSIONS: This review offers healthcare providers valuable insights into CSPC treatment trends. The findings aim to refine clinical guidelines, inform policymaking, improve resource allocation, and enhance market understanding globally.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD40
Topic
Real World Data & Information Systems
Disease
SDC: Oncology